ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025
Therapeutic applications of interface-mimicking peptides for targeting the SARS-CoV-2 NSP12-NSP8 RdRp complex.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication depends on the NSP12-NSP8-NSP7 complex, which plays a critical role in enhancing RNA-dependent RNA polymerase (RdRp) activity. NSP8 is particularly essential, stabilizing the RdRp complex and supporting viral replication across diverse variants. To disrupt this crucial interaction, we designed four NSP8-derived peptides-N8-Pepα, N8-Pepα_cyc, N8-Pepβ, and N8-PepβD-targeting a key hotspot region within the NSP12-NSP8 interface that governs complex stability and processivity. In vitro assays demonstrated that these peptides effectively inhibit RdRp activity by disrupting the NSP12-NSP8 interaction, leading to significant reductions in SARS-CoV-2 replication in Vero E6 cells. Notably, intranasal administration of N8-Pepα or N8-Pepα_cyc (25 mg/kg) in Balb/c mice provided robust antiviral protection, alleviating weight loss and reducing mortality following challenge with a mouse-adapted SARS-CoV-2 strain. Both prophylactic and therapeutic treatments significantly lowered viral titers and minimized pathological damage in the nasal turbinates and lungs. These results highlight the NSP12-NSP8 interface as a novel and highly conserved target for antiviral therapy and establish NSP8-derived peptides, particularly N8-Pepα and N8-Pepα_cyc, as promising candidates for inhibiting RdRp complex formation and controlling SARS-CoV-2 replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.